EMA issues negative opinion on Sarepta-Roche's DMD gene therapy
Source: SeekingAlpha
2025-07-25 07:15:15 ET
More on Sarepta Therapeutics, Roche Holding
- Roche: Q2 Earnings - Pipeline Setbacks And U.S. Pressures Undermine Solid Results
- Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
- Strategic Restructure and ELEVIDYS Label Update Call
- Sarepta drops as report suggests FDA needs new trials for Elevidys
- Roche eyes direct-to-patient sales in U.S. to avoid pharma middlemen
Read the full article on Seeking Alpha
For further details see:
EMA issues negative opinion on Sarepta-Roche’s DMD gene therapy
Champion Industries Inc
NASDAQ: CHMP
CHMP Trading
19900.0% G/L:
$0.02 Last:
342 Volume:
$0.02 Open:
CHMP Latest News
CHMP Stock Data
$7,319
24,723
21.8%
1
43%
Industrial Goods
Industrials
US
Huntington
